SEPNSepterna Inc.

Key Points15,000 shares were exercised and sold for a total of ~$533,000 on June 22, 2026, at a weighted average price of around $35.51 per share...

Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that the first detailed preclinical characterization of SEP-479 has been accepted for an oral presentation at the 2026 Endocrine Societys...

Septerna, Inc. (SEPN) delivered earnings and revenue surprises of +63.04% and +32.93%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Liquidia Corporation (LQDA) delivered earnings and revenue surprises of +54.76% and +22.11%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks (ZYME) delivered earnings and revenue surprises of -510.13% and -94.63%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Axsome (AXSM) delivered earnings and revenue surprises of -48.03% and +1.04%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Stifel Nicolaus initiated coverage on Septerna in a research note on Friday. They set a "buy" rating and a $43.00 price objective on the stock...

Septerna, Inc. (NASDAQ:SEPN - Get Free Report) saw a large growth in short interest during the month of April. As of April 15th, there was short interest totaling 2,457,303 shares, a growth of 12.9...

Shares of Septerna, Inc. (NASDAQ:SEPN - Get Free Report) have earned an average rating of "Moderate Buy" from the nine analysts that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, s...